Scarica l'app Stockscreener
1.48
7.25%
0.10
Dopo l'orario di chiusura:
1.52
0.04
+2.70%
Precedente Chiudi:
$1.38
Aprire:
$1.4
Volume 24 ore:
647.52K
Relative Volume:
1.58
Capitalizzazione di mercato:
$89.65M
Reddito:
-
Utile/perdita netta:
$-64.86M
Rapporto P/E:
-1.3214
EPS:
-1.12
Flusso di cassa netto:
$-55.66M
1 W Prestazione:
+13.85%
1M Prestazione:
+21.31%
6M Prestazione:
-10.30%
1 anno Prestazione:
-51.79%
Intervallo 1D:
$1.40
$1.55
Intervallo di 1 settimana:
$1.26
$1.55
Portata 52W:
$0.8551
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Nome
Acumen Pharmaceuticals Inc
Settore
Industria
Telefono
925-368-8508
Indirizzo
427 PARK ST., CHARLOTTESVILLE
Confronta ABOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.48 | 78.75M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-07-26 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-20 | Ripresa | BofA Securities | Buy |
| 2023-05-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Iniziato | BTIG Research | Buy |
| 2022-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-07-26 | Iniziato | BofA Securities | Neutral |
| 2021-07-26 | Iniziato | Credit Suisse | Outperform |
| 2021-07-26 | Iniziato | Stifel | Buy |
| 2021-07-26 | Iniziato | UBS | Buy |
Mostra tutto
Acumen Pharmaceuticals Inc Borsa (ABOS) Ultime notizie
Acumen and JCR enter collaboration to develop BBB-penetrating Alzheimer’s treatment - BioWorld MedTech
JCR Pharma links up with Acumen on Alzheimer’s research - The Pharma Letter
Acumen and JCR partner on brain delivery therapy for Alzheimer’s - Yahoo Finance
ai for factory safety and hazard detectionSafety First Trading Signals - Newser
What makes Acumen Pharmaceuticals Inc. stock price move sharplyFree Stock Market Beginners Guide - Newser
Why Acumen Pharmaceuticals Inc. stock attracts strong analyst attentionSafer Investing With Bigger Upside - Newser
Acumen Pharmaceuticals Inc (ABOS) Stock: A Comprehensive 52-Week Review - investchronicle.com
How Acumen Pharmaceuticals Inc. stock performs during market volatilityFree Exclusive Group - Newser
Why Veeco Instruments Inc. stock attracts strong analyst attentionFree Top Growth Stock Recommendations - Newser
How SELX stock performs during market volatilityVerified Return Tips - Newser
Compass Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Acumen Pharmaceuticals, JCR to Develop Alzheimer's Disease Therapy - MarketScreener
Acumen, JCR partner on brain barrier technology for Alzheimer’s treatment By Investing.com - Investing.com Canada
ABOS SEC FilingsAcumen Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Acumen, JCR partner on brain barrier technology for Alzheimer’s treatment - Investing.com
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease - The Manila Times
JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform - MarketScreener
Why AFMD stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025 - The Manila Times
Acumen Pharmaceuticals to Present Findings on Sabirnetug at Alzheimer's Association International Conference 2025 - Nasdaq
New Alzheimer's Drug Trial Shows Major Cost Savings: Acumen Reveals Breakthrough Screening Method - Stock Titan
Cognition Therapeutics (CGTX) Soars 12% After-Hours on Alzheimer's Trial Data - AInvest
Acumen Pharmaceuticals (NASDAQ:ABOS) Trading Up 4.3% – Still a Buy? - Defense World
Bessemer Group Inc. Purchases 69 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Halozyme Therapeutics Added to Russell 1000® Index - The Malaysian Reserve
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - The Malaysian Reserve
Acumen Pharmaceuticals (NASDAQ:ABOS) Now Covered by Citigroup - Defense World
Citi initiates Acumen Pharmaceuticals stock with buy rating By Investing.com - Investing.com South Africa
Citigroup Initiates Coverage on Acumen Pharmaceuticals (ABOS) wi - GuruFocus
Bank of America Corp DE Boosts Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Cantor Fitzgerald Estimates ABOS FY2026 Earnings - Defense World
Pre-market Movers: EVGN, WINT, CARM, UNCY... - RTTNews
Two Sigma Investments LP Lowers Holdings in Vicor Co. (NASDAQ:VICR) - Defense World
Two Sigma Investments LP Sells 8,239 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Acumen Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Deutsche Bank AG Increases Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Millennium Management LLC Acquires New Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Millennium Management LLC Cuts Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Cryptocurrency Stocks To Follow Today – May 30th - Defense World
Halozyme to Participate at Upcoming Investor Conferences - The Malaysian Reserve
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - Quantisnow
Cancer Immunotherapy Market Detailed Analysis and Forecast - openPR.com
FY2025 EPS Estimates for ABOS Reduced by Cantor Fitzgerald - Defense World
Dimensional Fund Advisors LP Purchases 41,460 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Acumen targets ALTITUDE-AD Phase 2 topline results in late 2026 while advancing subcutaneous Sabirnetug development - MSN
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Ovid Therapeutics (OVID) - The Globe and Mail
Acumen Pharmaceuticals’ Earnings Call Highlights Progress in Alzheimer’s Treatment - TipRanks
Tower Research Capital LLC TRC Purchases 16,714 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Transcript : Acumen Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2025 Earnings Call Transcript - Insider Monkey
Barclays PLC Raises Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Acumen Pharmaceuticals Inc Azioni (ABOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):